Drug product
Valsartan and Hydrochlorothiazide tablets USP 160 mg/25 mg, 90-count bottle, Rx Only, Manufactured for: Aurobindo Pharma USA, Inc., Dayton, NJ 08810. NDC 65862-549-90.
D-0369-2019
Product summary
- Event
- Event 81887
- Status
- Ongoing
- Classification
- Class II
- Quantity
- 53,064 bottles
- Official record key
drug-enforcement:D-0369-2019
Official wording
Reason: CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
Code information: Lot # HVSB17023-A, exp. date 08/2020 Lot # HVSB17036-A, exp. date 11/2020 Lot # HVSB17037-A, exp. date 11/2020 Lot # HVSB17038-A, exp. date 11/2020 Lot # HVSB17039-A, exp. date 11/2020 Lot # HVSB17040-B, exp. date 11/2020 Lot # HVSB18001-A, exp. date 12/2020 Lot # HVSB18002-A, exp. date 12/2020 Lot # HVSB18003-A, exp. date 12/2020 Lot # HVSB18004-A, exp. date 12/2020
Distribution pattern: Product was distributed to 25 distributors and Retail Chains who may have further distributed the product throughout the United States.
Derived failure modes
-
Foreign material or chemical contamination
impurity, N-nitrosodimethylamine (NDEA
-
Manufacturing or process control
CGMP Deviations